Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026)

Myriad Genetics (MYGN) has reported Cash from Investing Activities for 18 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.69% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$25.6 million (down 95.42% YoY), while the FY2025 annual figure was -$27.4 million, down 130.25% from the prior year.
• Cash from Investing Activities eased to -$6.5 million in Q1 2026 per MYGN's latest filing, from -$6.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $34.6 million in Q1 2023 and bottomed at -$41.3 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$5.4 million across 5 years, with a median of -$6.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 1190.91% — and 2024, when it surged 400.0%.
• Myriad Genetics' Cash from Investing Activities stood at -$35.6 million in 2022, then soared by 66.29% to -$12.0 million in 2023, then surged by 50.83% to -$5.9 million in 2024, then slipped by 1.69% to -$6.0 million in 2025, then fell by 8.33% to -$6.5 million in 2026.
• Business Quant data shows MYGN's Cash from Investing Activities at -$6.5 million in Q1 2026, -$6.0 million in Q4 2025, and -$6.2 million in Q3 2025.